Conclusion Clinical trial data from large, controlled studies demonstrate the efficacy and safety of GLP-1 agonists in terms of A1C reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy
Neuropeptides (2018) 71:7080
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Whether have recently been diagnosed with cancer or are entering remission, education and support are essential
Additionally, pricing can differ from pharmacy to pharmacy, so patients may find it beneficial to shop around for the best deals or explore options like online pharmacies
Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M